Human TMEM30A (Transmembrane protein 30A) knockout HeLa cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
TMEM30A KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon1 and Insertion of the selection cassette in exon1.
View Alternative Names
C6orf67, CDC50A, Cell cycle control protein 50A, FLJ10856, P4 ATPase flippase complex beta subunit TMEM30A, TMEM30A
- Sanger seq
Unknown
Sanger Sequencing - Human TMEM30A (Transmembrane protein 30A) knockout HeLa cell lysate (AB263391)
Allele-2 : Insertion of the selection cassette in exon1
- Sanger seq
Unknown
Sanger Sequencing - Human TMEM30A (Transmembrane protein 30A) knockout HeLa cell lysate (AB263391)
Allele-1 : 7 bp deletion in exon1
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
TMEM30A is critical in maintaining lipid asymmetry in cell membranes. It acts within a larger complex with flippases such as ATP11 and ATP8 proteins enabling the efficient translocation of phospholipids. This activity affects membrane curvature and flexibility which is essential for cellular processes like vesicle formation endocytosis and maintenance of membrane integrity. Disruption in TMEM30A function can result in altered cellular homeostasis impacting cell viability and signaling.
Pathways
TMEM30A plays a significant part in the phospholipid flipping pathway chiefly interacting with ATP11C in energizing the lipid translocation process. This pathway is fundamental for activities like signal transduction and apoptosis where these lipids serve as substrates or signaling molecules. The protein also interrelates with the calcium signaling pathway wherein altered phospholipid distribution can influence calcium ion channels therefore impacting cellular responses and homeostasis.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female
Complementary Products
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com